What drives HIV prevention choices for women who inject drugs?
NCT ID NCT05799339
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at how women who inject drugs view a long-acting injectable HIV prevention medication called CAB-LA. Researchers interviewed 144 women to understand what influences their decisions to use this option versus daily pills. The goal is to learn how to better support this group in preventing HIV.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cabotegravir (CAB-LA) long-acting injectable PrEP
What this could lead to
If successful, this research could help design better HIV prevention programs tailored for women who inject drugs.
What could go wrong
This is a small, completed study focused on gathering opinions and early engagement data, not testing effectiveness. Results may not apply to all populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Prevention Point Philadelphia
Philadelphia, Pennsylvania, 19143, United States